Matt Phipps
Stock Analyst at William Blair
(0.19)
# 4,485
Out of 4,666 analysts
15
Total ratings
28.57%
Success rate
-35.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Initiates: Outperform | n/a | $22.74 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $4.86 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $13.10 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $58.23 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $7.38 | - | 2 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $49.01 | - | 1 | Nov 14, 2022 | |
| GMAB Genmab | Initiates: Market Perform | n/a | $20.50 | - | 1 | Nov 14, 2022 | |
| ALRN Aileron Therapeutics | Downgrades: Market Perform | n/a | $2.82 | - | 1 | Jun 29, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.69 | - | 1 | Nov 9, 2021 | |
| TPST Tempest Therapeutics | Initiates: Outperform | n/a | $0.87 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $20.69 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $155.43 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.49 | - | 1 | Apr 8, 2021 |
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $22.74
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.86
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $13.10
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $58.23
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.38
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $49.01
Upside: -
Genmab
Nov 14, 2022
Initiates: Market Perform
Price Target: n/a
Current: $20.50
Upside: -
Aileron Therapeutics
Jun 29, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.82
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.69
Upside: -
Tempest Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.87
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.69
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $155.43
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $43.49
Upside: -